Covid-19 Outbreak characterization in Buenaventura. Epidemiological week 22 of 2020
DOI:
https://doi.org/10.33610/01229907.2020v2n3a1Keywords:
Coronavirus, Mortality, Polymerase Chain Reaction (PCR), ColombiaAbstract
Background: The first case of COVID19 was reported in Colombia on March 6, 2020, and on March 26, the first case in the district of Buenaventura. By May 26, there were 282 confirmed cases with an incidence rate of 90,4 per 100 000 inhabitants and lethality of 6,7 %, being double at the national level. The objective of this research was to characterize the Covid-19 outbreak and describe control and mitigation measures.
Materials and methods: For the Covid19 outbreak study, we included all positive laboratory cases diagnosed between March 26 and June 3. We performed an active institutional and community search. We calculated central tendency and dispersion for quantitative variables and absolute and relative frequencies and proportions for qualitative variables.
Results: By June 3, 2020, we found 575 confirmed positive cases for SARS-CoV-2. 66.2% (375) were men, the median age was 46,5 years (IQR 26,7 – 66,2); 2,1 % (10) of the active cases were in the ICU, and 12,1 % (58) were hospitalized. Lethality was 6,2 %, and the most frequent comorbidities in the deceased were arterial hypertension (42 %), diabetes mellitus (36 %), renal failure (22,2 %) and obesity (13,9 %).
Conclusions: An outbreak of Covid-19 is confirmed with a high frequency in men, a high case fatality rate in patients with advanced age and mainly metabolic and pulmonary comorbidities. It is necessary to continue with prevention, control and education actions to reduce transmission in the community.
References
Salud OP de la. Reporte de situación COVID-19 Colombia No. 72: 03 de junio de 2020. 2020;13–13.
Organización Mundial de la Salud. Recomendaciones sobre el uso de mascarillas en el contexto de la COVID-19. 5. 2020;(1):18.
Organización Panamericana de Salud. Material para la comunicación de riesgos sobre la COVID-19 para los establecimientos de salud. 2020;1–11.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
Organization WH. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [In- ternet]. WHO Director General’s speeches. 2020. p. 4. Available from: https://www.who.int/dg/speeches/detail/who-di- rector-general-s-opening-remarks-at-themedia-briefing-on-COVID-19 11-march-2020
OMS | Neumonía de causa desconocida - China.
Los nombres de la enfermedad por coronavirus (COVID-19) y del virus que la causa.
IETS A. Síndrome Post COVID-19: Complicaciones tardías y rehabilitación Resumen: Preguntas y Recomendaciones. In: Instituto de Evaluación de las Tecnologías en Salud, editor. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARSCoV-2/COVID-19 en establecimientos de atención de la salud 12 de marzo de 2021 [Internet]. Bo- gotá: Asociación Colombiana de Infectología; 2021. p. 6. Available from: http://www.acin.org/images/guias/coronavirus/Recomendaciones_sindrome_post_COVD19_ACIN_IETS_sg_chs.pdf
Distrita S de S. Comunicado - Primer caso positivo COVID-19 en Buenaventura.
Instituto Nacional de Salud. COVID 19 en Colombia [Internet]. 2021 [cited 2021 Feb 23]. p. 3. Available from: https:// www.ins.gov.co/Noticias/Paginas/coronavirus-casos.aspx
Instituto Nacional de Salud de Colombia, Ministerio de Salud y Protección Social de Colombia. Casos COVID-19. Colombia 202-2021 [Internet]. Instituto Nacional De Salud. 2021. p. 1– 4. Available from: https://app.powerbi.com/view?r=eyJrIjoiMjBjZWNlOGUtNzc1Yi00NjVkLTkyMjktOTJmMGU3YTU2Nzk4IiwidCI6ImE2MmQ2YzdiLTlmNTktN DQ2OS05MzU5LTM1MzcxNDc1OTRiYiIsImMiOjR9&pageName=ReportSection0c50ea3406afe4407370
Buenaventura - Google Maps. 15
Malagón-Rojas J, Ibáñez E, Parra ELB, Toloza-Pérez YG, Álvarez S, Mercado M. Analysis of COVID-19 mortality and survival in Colombia: A prospective cohort study. Infectio [Internet]. 2021;25(3):176–81. Available from: https://orcid. org/0000-0001-7715-8808
Instituto Nacional de Salud., Colombia. Coronapp [Internet]. Ministerio De Salud Y Protección Social. 2020 [cited 2021 May 13]. p. 1. Available from: https://coronaviruscolombia.gov.co/COVID19/coronApp/registro-coronApp.html
Instituto Nacional de Salud de Colombia. Casos COVID Colombia, 2020-2021 [Internet]. SIVIGILA, Instituto Nacional de Salud. 2021 [cited 2021 May 14]. p. 1–4. Available from: https://app.powerbi.com/view?r=eyJrIjoiMjBjZWNlOGUtNzc1Yi00NjVkLTkyMjktOTJmMGU3YTU2Nzk4IiwidCI6ImE2MmQ2YzdiLTlmNTktNDQ2OS05MzU5LTM 1MzcxND- c1OTRiYiIsImMiOjR9&pageName=ReportSection0c50ea3406afe4407370
Instituto Nacional de Salud de Colombia. Lineamientos Nacionales 2021. Vol. 1. Bogotá; 2021.
Instituto Nacional de Salud de Colombia. PROCESO VIGILANCIA Y ANÁLISIS DEL RIESGO EN SALUD PÚBLICA [Internet]. Bogotá: Instituto Nacional de Salud; 2018. p. 1–12. Available from: https://www.ins.gov.co/conocenos/sig/SIG/ POE-R02.4220-001.pdf
Instituto Nacional de Salud de Colombia. Anexo. Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda y la enfermedad asociada al nuevo coronavirus 2019 (COVID-19). Este [Internet]. Vol. 21, Instituto Nacional De Salud. Bogotá D.C.: Instituto Nacional de Salud; 2020. p. 1–9. Available from: https://doi. org/10.1016/j.tmaid.2020.101607%0Ahttps://doi.org/10.1016/j.ijsu.2020.02.034%0Ahttps://onlinel ibrary.wiley. com/doi/abs/10.1111/cjag.12228%0Ahttps://doi.org/10.1016/j.ssci.2020.104773%0Ahttps://doi.or g/10.1016/j. jinf.2020.04.011%0Ahttps://doi.o
Unidad de Evidencia y Deliberacion (UNED). Factores clínicos pronósticos de enfermedad grave y mortalidad en pacientes con COVID-19. Univ Antioquia [Internet]. 2020;1(1):57. Available from: http://fi-admin.bvsalud.org/document/view/rpncv NS
Diaz-Pinzón JE. Descripción estadística del COVID- 19 según el grupo etario en Colombia. Obes Un Probl En La Aten COVID-19. 2020;29:10–4.
Marín-Sánchez A. Características clínicas básicas en los primeros 100 casos fatales de COVID-19 en Colombia. Rev Panam Salud Publica/Pan Am J Public Heal. 2020;44(1):1–4.
Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020;17(9):1–11. Reporte Epidemiológico Nacional Volumen 2 Número 3 – septiembre – diciembre de 2020 16
DANE. Defunciones por COVID-19. 2020; Available from: https://www.dane.gov.co/files/investigaciones/poblacion/de- funciones-COVID19/presentaciondefunciones-COVID-2020-02mar-23ago.pdf
Cárcamo LMC, Tejeda MJ, Castro J, Montoya L, Barrezueta LJ, Cardona S, et al. Características clínicas y sociodemográ- ficas de pacientes fallecidos por COVID-19 en Colombia. 2020;7(916):3862116.
Abrams EM, Szefler SJ. COVID-19 and the impact of social determinants of health. Vol. 8, The Lancet Respiratory Medi- cine. Lancet Publishing Group; 2020. p. 659–61.
Rodriguez-Morales AJ, Sánchez-Duque JA, Hernández Botero S, Pérez-Díaz CE, VillamilGómez WE, Méndez CA, et al. Preparación y control de la enfermedad por coronavirus 2019 (COVID-19) en América Latina [Preparation and control of the coronavirus disease 2019 (COVID19) in Latin America]. Acta Medica Peru. 2020;37(1):3–7.
Manual para la prevención y tratamiento de COVID-19 Manual para la prevención y tratamiento de COVID-19. 19:1–64.
Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MCJ, Rozhnova G. Impact of self-imposed prevention measu- res and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study. PLoS Med. 2020;17(7):1–21.
Siedner MJ, Harling G, Reynolds Z, Gilbert RF, Haneuse S, Venkataramani AS, et al. Social distancing to slow the US CO- VID-19 epidemic: Longitudinal pretest–posttest comparison group study. PLoS Med. 2020;17(8 August):1–12.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Reporte Epidemiológico Nacional
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
